Jade Biosciences, Inc.
JBIONext catalyst
Phase 1 — JADE201
Get an email about JBIO's next catalysts
Track Jade Biosciences (JBIO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
JBIO Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.73 | FQ end Sep/2026 | Call: tbd
Phase 1 — JADE201
For autoimmune diseases. Jade Biosciences announced dosing of the first participant in a Phase 1 clinical trial of JADE201, a novel afucosylated anti-BAFF receptor monoclonal antibody designed to treat autoimmune diseases. The company expects to report interim Phase 1 data in 2027.
SourceHow JBIO's past catalysts played out
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
JADE101 | Phase 3 | IgA Nephropathy | - | - |
Frequently asked questions
What is in Jade Biosciences, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Jade Biosciences, Inc.'s (JBIO) pipeline across Phase 3. Its lead program is JADE101 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Jade Biosciences, Inc.'s next FDA catalyst?→
Jade Biosciences, Inc.'s (JBIO) next tracked catalyst is a Phase 1 readout expected Jan 1, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track JBIO biotech catalysts?→
Add JBIO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Jade Biosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.